Effect of multiple doses of oral tranexamic acid on perioperative hemostasis and inflammatory reaction following total hip arthroplasty: a randomized placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011669

Enrollment

Unknown

Registered

2017-06-15

Start date

2017-06-15

Completion date

Unknown

Last updated

2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip osteoarthritis

Interventions

A:Control group(Plcabo)

B:2g oral TXA 2h before surgery, 1g oral TXA 3h postoperatively

C:2g oral TXA 2h before surgery, 1g oral TXA 3h and 7h postoperatively

D:2g oral TXA 2h before surgery, 1g oral TXA 3h,7h, and 11h postoperatively

E:2g oral TXA 2h before surgery, 1g oral TXA 3h,7h, 11h, and 15h postoperatively

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Primary unilateral total hip artropasty; (2) Normal platelet and coagulation function preoperatively; (3) Normal intravenous ultrasound in the lower extremities preoperatively; (4) Able and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Systemic infections such as pulmonary infection or urinary tract infection are not controlled preoperatively; (2) Abnormal immune function or combined immune-related disease preoperatively; (3) Abnormal inflammatory index preoperatively (C-reactive protein >20 mg/L); (4) Abnormal fibrinolysis index preoperatively (FDP > 5mg/L); (5) Discontinuation of oral anticoagulants or aspirin less than 1 week; (6) Allergy to tranexamic acid (TXA) or dexamethasone or have contraindications; (7) Patients at high risk of thrombosis; (8) History of deep vein thrombosis (VTE, calf muscle vein thrombosis or superficial vein thrombosis, pulmonary embolism); (9) serious liver and kidney dysfunction.

Design outcomes

Primary

Measure	Time frame
Blood loss;	—

Secondary

Measure	Time frame
Hb level;Hct;ESR, CRP, IL-6,IL-10;TEG;hip function evaluation;DVT, PE;Transfusion;Swelling;pain;	—

Countries

China

Contacts

Public ContactZhou Zongke

West China Hospital, Sichuan University

zongke@126.com+86 18980601028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026